Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free CRVO Stock Alerts

CervoMed (CRVO) Financials

CervoMed logo
$3.14 +0.07 (+2.28%)
Closing price 07/16/2026 04:00 PM Eastern
Extended Trading
$3.07 -0.07 (-2.23%)
As of 07/16/2026 07:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for CervoMed

Annual Income Statements for CervoMed

This table shows CervoMed's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -6.72 -18 -2.62 -27 -12 -16 -24 -5.80 -2.17 -16 -27
Consolidated Net Income / (Loss)		 -6.72 -18 -1.36 -18 -12 -14 -24 -5.80 -2.17 -16 -27
Net Income / (Loss) Continuing Operations		 -6.72 -18 -1.36 -18 -12 -14 -24 -5.80 -2.17 -16 -27
Total Pre-Tax Income 		-6.72 -18 -2.42 -19 -11 -16 -25 -5.80 -2.17 -16 -27
Total Operating Income		 -6.41 -18 -11 -19 -12 -16 -25 -3.48 -7.81 -18 -28
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 7.14 9.74 4.01
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 7.14 9.74 4.01
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 6.41 18 11 19 12 16 25 3.48 15 28 32
Selling, General & Admin Expense		 2.52 11 6.19 6.17 4.83 6.44 7.45 2.14 6.52 9.17 10
Research & Development Expense		 3.88 7.25 5.09 5.75 6.62 9.43 8.50 1.34 8.44 19 22
Total Other Income / (Expense), net		 -0.31 -0.03 8.93 0.15 0.09 0.11 0.14 -2.33 5.64 1.94 1.33
Interest & Investment Income		 - -0.03 -0.05 0.15 0.09 0.11 0.14 0.06 0.22 1.94 1.34
Other Income / (Expense), net		 - 0.00 8.98 - - - - -2.39 5.42 -0.00 -0.01
Basic Earnings per Share		 ($2.56) ($1.76) ($3.16) ($8.21) ($1.76) ($0.30) ($12.38) ($11.20) ($0.82) ($2.02) ($2.98)
Weighted Average Basic Shares Outstanding		 2.62M 10.23M 827.58K 3.38M 34.60M 101.90M 101.92M 518.14K 2.66M 8.07M 9.04M
Weighted Average Diluted Shares Outstanding		 2.62M 10.23M 848.09K 3.38M 34.60M 101.90M 101.92M 2.04M 6.17M 8.70M 9.26M
Weighted Average Basic & Diluted Shares Outstanding		 2.62M 10.23M 50.53M 3.38M 34.60M 101.90M 101.92M 2.04M 6.17M 8.70M 9.26M

Quarterly Income Statements for CervoMed

This table shows CervoMed's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 2.15 -2.36 -2.51 -2.32 -4.75 -6.71 -4.89 -6.26 -7.73 -8.09 -7.96
Consolidated Net Income / (Loss)		 2.15 -2.36 -2.51 -2.32 -4.75 -6.71 -4.89 -6.26 -7.73 -8.09 -7.96
Net Income / (Loss) Continuing Operations		 2.15 -2.36 -2.51 -2.32 -4.75 -6.71 -4.89 -6.26 -7.73 -8.09 -7.96
Total Pre-Tax Income 		2.15 -2.36 -2.51 -2.32 -4.75 -6.71 -4.89 -6.26 -7.73 -8.09 -7.96
Total Operating Income		 -2.68 -2.48 -2.59 -3.00 -5.40 -7.24 -5.30 -6.62 -8.04 -8.33 -8.11
Total Gross Profit		 1.53 2.49 2.35 3.29 1.94 2.16 1.92 1.76 0.32 0.01 0.00
Total Revenue		 1.53 2.49 2.35 3.29 1.94 2.16 1.92 1.76 0.32 0.01 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 4.20 4.97 4.94 6.28 7.34 9.40 7.22 8.37 8.37 8.34 8.11
Selling, General & Admin Expense		 2.41 2.12 2.13 2.51 2.21 2.32 2.38 3.27 2.33 2.51 2.98
Research & Development Expense		 1.79 2.86 2.81 3.77 5.13 7.09 4.84 5.11 6.04 5.83 5.14
Total Other Income / (Expense), net		 4.83 0.12 0.08 0.68 0.64 0.53 0.41 0.36 0.32 0.24 0.15
Interest & Investment Income		 0.05 0.12 0.08 0.68 0.65 0.53 0.41 0.37 0.32 0.24 0.15
Other Income / (Expense), net		 4.78 -0.00 -0.00 -0.00 -0.00 0.00 -0.00 -0.01 -0.00 0.00 -0.00
Basic Earnings per Share		 $0.65 $2.31 ($0.41) ($0.27) ($0.55) ($0.79) ($0.56) ($0.70) ($0.84) ($0.88) ($0.86)
Weighted Average Basic Shares Outstanding		 3.31M 2.66M 6.17M 8.70M 8.70M 8.07M 8.70M 8.95M 9.25M 9.04M 9.26M
Weighted Average Diluted Shares Outstanding		 3.77M 6.17M 8.25M 8.25M 8.25M 8.70M 8.70M 9.25M 9.25M 9.26M 9.26M
Weighted Average Basic & Diluted Shares Outstanding		 5.67M 6.17M 8.25M 8.25M 8.25M 8.70M 8.70M 9.25M 9.25M 9.26M 9.26M

Annual Cash Flow Statements for CervoMed

This table details how cash moves in and out of CervoMed's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -0.34 -0.44 7.34 -0.91 6.19 4.34 19 -2.57 3.70 1.21 -0.76
Net Cash From Operating Activities		 -5.19 -11 -12 -11 -9.86 -14 -15 -2.57 -7.45 -17 -23
Net Cash From Continuing Operating Activities		 -5.19 -11 -12 -11 -9.86 -14 -15 -2.57 -7.45 -17 -23
Net Income / (Loss) Continuing Operations		 -6.72 -18 -1.36 -18 -12 -14 -24 -5.80 -2.17 -16 -27
Consolidated Net Income / (Loss)		 -6.72 -18 -1.36 -18 -12 -14 -24 -5.80 -2.17 -16 -27
Amortization Expense		 0.31 0.04 0.03 - - - 0.00 - - -1.21 -0.85
Non-Cash Adjustments To Reconcile Net Income		 0.60 6.26 -7.69 8.20 0.52 0.74 9.59 2.85 -5.02 1.41 1.45
Changes in Operating Assets and Liabilities, net		 0.62 0.95 -3.38 -0.71 1.33 -0.21 -0.09 0.38 -0.26 -0.44 2.92
Net Cash From Investing Activities		 2.46 8.50 -0.45 0.00 0.00 0.00 0.00 0.00 0.00 -29 18
Net Cash From Continuing Investing Activities		 2.46 8.50 -0.45 0.00 0.00 0.00 0.00 0.00 0.00 -29 18
Purchase of Investments		 - - - - - - 0.00 - 0.00 -48 -25
Sale and/or Maturity of Investments		 2.50 0.00 10 - - - 0.00 - 0.00 19 44
Net Cash From Financing Activities		 2.39 1.83 20 9.87 16 18 33 0.00 11 46 4.59
Net Cash From Continuing Financing Activities		 2.39 1.83 20 9.87 16 18 33 0.00 11 46 4.59
Issuance of Common Equity		 - - 0.00 - 0.00 11 31 0.00 0.81 46 4.59

Quarterly Cash Flow Statements for CervoMed

This table details how cash moves in and out of CervoMed's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 9.77 -2.63 -1.42 3.64 -2.27 1.26 1.50 -2.18 1.12 -1.20 -0.29
Net Cash From Operating Activities		 -1.47 -2.54 -1.42 -2.20 -4.85 -8.05 -3.89 -6.51 -6.47 -6.58 -8.02
Net Cash From Continuing Operating Activities		 -1.47 -2.54 -1.42 -2.22 -4.83 -8.05 -3.89 -6.51 -6.47 -6.58 -8.02
Net Income / (Loss) Continuing Operations		 2.15 -2.36 -2.51 -2.32 -4.75 -6.71 -4.89 -6.26 -7.73 -8.09 -7.96
Consolidated Net Income / (Loss)		 2.15 -2.36 -2.51 -2.32 -4.75 -6.71 -4.89 -6.26 -7.73 -8.09 -7.96
Amortization Expense		 - - - - -0.48 -0.38 -0.25 - -0.22 -0.15 -0.07
Non-Cash Adjustments To Reconcile Net Income		 -4.67 0.16 0.22 0.56 0.29 0.34 0.36 0.75 0.29 0.30 0.35
Changes in Operating Assets and Liabilities, net		 1.05 -0.34 0.87 -0.13 0.11 -1.30 0.89 -0.52 1.19 1.36 -0.33
Net Cash From Investing Activities		 - - 0.00 -41 2.60 9.31 5.40 -0.25 7.58 5.37 7.71
Net Cash From Continuing Investing Activities		 - - 0.00 -41 2.60 9.31 5.40 -0.25 7.58 5.37 7.71
Purchase of Investments		 - - 0.00 -41 -3.90 -3.63 -7.10 -9.75 -3.92 -4.63 -0.99
Sale and/or Maturity of Investments		 - - 0.00 - 6.50 13 13 9.50 12 10 8.70
Net Cash From Financing Activities		 11 -0.09 0.00 46 -0.01 - 0.00 4.59 - - 0.01
Net Cash From Continuing Financing Activities		 11 -0.09 0.00 46 -0.01 - 0.00 4.59 - - 0.01
Other Financing Activities, net		 - - - - - - 0.00 - - - 0.01

Annual Balance Sheets for CervoMed

This table presents CervoMed's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 2.28 17 26 18 24 28 38 4.16 9.97 43 23
Total Current Assets		 2.04 1.60 9.67 8.91 15 19 38 4.16 9.96 43 23
Cash & Equivalents		 2.00 1.55 8.90 7.99 14 19 37 4.09 7.79 9.00 8.24
Short-Term Investments		 - - - - - - 0.00 - 0.00 30 13
Prepaid Expenses		 0.05 0.05 0.77 0.92 0.47 0.26 0.51 0.06 1.26 1.91 1.27
Other Current Assets		 - - - - - - - 0.00 0.92 2.25 0.75
Plant, Property, & Equipment, net		 0.05 0.08 0.46 0.35 0.25 0.15 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.18 16 16 8.94 9.21 8.80 0.02 0.00 0.01 0.00 0.00
Total Liabilities & Shareholders' Equity		 2.28 17 26 18 24 28 38 4.16 9.97 43 23
Total Liabilities		 2.32 8.30 4.92 2.59 3.98 2.92 2.93 13 2.60 3.88 4.66
Total Current Liabilities		 1.47 4.44 2.69 0.80 1.72 2.44 2.93 13 2.60 3.88 4.66
Accounts Payable		 0.42 1.68 0.51 0.20 1.25 0.55 0.95 0.10 0.66 1.51 1.45
Accrued Expenses		 0.62 0.87 1.63 0.61 0.36 1.78 1.98 0.64 1.93 2.37 3.20
Total Noncurrent Liabilities		 0.85 3.86 2.23 1.79 2.25 0.48 0.00 0.00 0.00 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 - 0.00
Total Equity & Noncontrolling Interests		 -0.04 9.18 21 16 20 25 35 -33 7.38 39 18
Total Preferred & Common Equity		 -0.04 9.18 21 16 20 25 35 -33 7.38 39 18
Preferred Stock		 - - - - - - - - - 0.00 0.00
Total Common Equity		 -0.04 9.18 21 16 20 25 35 -33 7.38 39 18
Common Stock		 42 69 83 96 112 131 165 19 62 110 116
Retained Earnings		 -42 -60 -62 -80 -92 -106 -130 -52 -54 -71 -98
Accumulated Other Comprehensive Income / (Loss)		 - - - - - - 0.00 - 0.00 0.06 0.01

Quarterly Balance Sheets for CervoMed

This table presents CervoMed's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 12 8.00 53 49 39 38 31 15
Total Current Assets		 12 7.97 47 49 39 38 31 15
Cash & Equivalents		 10 6.37 10 7.74 11 8.32 9.44 7.94
Short-Term Investments		 - - 35 39 25 25 18 4.98
Prepaid Expenses		 1.42 1.35 2.24 1.89 1.70 1.96 1.69 1.70
Other Current Assets		 - 0.25 0.00 0.26 1.63 2.36 1.36 0.49
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.19 0.03 5.86 0.07 0.00 0.22 0.27 0.00
Total Liabilities & Shareholders' Equity		 12 8.00 53 49 39 38 31 15
Total Liabilities		 2.46 2.66 3.21 3.25 3.94 4.64 4.60 4.50
Total Current Liabilities		 2.46 2.66 3.21 3.25 3.94 4.64 4.60 4.50
Accounts Payable		 0.53 0.68 0.73 1.08 1.86 1.85 1.35 2.27
Accrued Expenses		 1.38 1.41 1.09 2.16 2.08 2.80 3.25 2.22
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 9.57 5.34 50 46 35 33 26 11
Total Preferred & Common Equity		 9.57 5.34 50 46 35 33 26 11
Preferred Stock		 - 0.00 - - 0.00 0.00 0.00 0.00
Total Common Equity		 9.57 5.34 50 46 35 33 26 11
Common Stock		 62 62 109 110 110 115 116 116
Retained Earnings		 -52 -57 -59 -64 -76 -82 -90 -106
Accumulated Other Comprehensive Income / (Loss)		 - - -0.02 0.12 0.02 -0.00 0.01 -0.00

Annual Metrics And Ratios for CervoMed

This table displays calculated financial ratios and metrics derived from CervoMed's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 18,614,968.00 10,345,637.00 14,521,730.00 50,643,429.00 4,693,290.00 64,015,441.00 101,920,329.00 2,039,442.00 5,674,520.00 8,253,741.00 9,252,719.00
DEI Adjusted Shares Outstanding		 18,614,968.00 10,345,637.00 14,521,730.00 50,643,429.00 4,693,290.00 64,015,441.00 101,920,329.00 2,039,442.00 5,674,520.00 8,253,741.00 9,252,719.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.36 -1.74 -0.18 -0.53 -2.51 -0.25 -0.24 -2.85 -0.38 -1.97 -2.91
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 36.29% -58.86%
EBITDA Growth		 62.74% -200.85% 87.60% -730.07% 39.23% -38.57% -54.89% 76.14% 59.23% -712.67% -50.04%
EBIT Growth		 62.09% -186.78% 87.09% -699.21% 39.07% -38.29% -54.47% 76.23% 59.23% -662.27% -55.27%
NOPAT Growth		 56.16% -186.78% 38.23% -67.06% 39.07% -38.29% -54.47% 85.92% -124.80% -133.30% -55.23%
Net Income Growth		 53.19% -168.43% 92.43% -1,246.25% 35.77% -20.22% -69.86% 75.92% 62.57% -650.08% -65.53%
EPS Growth		 -156.00% 31.25% -1,553.98% 11,138,200.31% 106.84% 702.68% -96.38% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 42.58% -107.67% -14.53% 12.65% 8.49% -37.47% -7.00% 82.26% -189.57% -121.89% -41.86%
Free Cash Flow Firm Growth		 168.31% -288.34% 54.61% 25.61% 19.80% -79.43% 25.74% 51.24% -37.32% -134.81% -25.49%
Invested Capital Growth		 -104.88% 1,365.31% 28.04% -40.85% -21.83% 5.74% -138.38% 71.98% 38.58% 167.37% -1,042.37%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 53.51% -3.26% -34.96%
EBITDA Q/Q Growth		 64.36% -38.57% 59.02% -19.70% 18.47% -79.71% 21.00% 55.47% -366.77% -44.26% -7.14%
EBIT Q/Q Growth		 61.79% -37.18% 57.86% -19.57% 18.35% -78.75% 20.93% 55.47% -366.77% -35.31% -4.01%
NOPAT Q/Q Growth		 61.79% -37.18% 0.83% -19.57% 18.35% -78.75% 20.93% 73.61% -710.11% -35.35% -4.01%
Net Income Q/Q Growth		 51.92% -35.85% 76.17% -66.86% 13.36% -2.23% 2.38% 55.61% -154.47% -36.36% -5.40%
EPS Q/Q Growth		 -100.00% 42.11% -662.04% -66.07% 17.72% -62.92% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -6.92% 7.33% -7.57% -7.43% 5.64% -7.59% 2.48% 47.56% -32.94% -50.03% 5.92%
Free Cash Flow Firm Q/Q Growth		 282.05% -47.94% -249.23% 68.37% 13.13% -102.50% 33.29% 63.47% -428.04% -45.34% 10.09%
Invested Capital Q/Q Growth		 -118.76% -7.65% 397.58% -22.94% -19.27% -7.57% -9.72% 0.00% 51.08% 127.50% -105.95%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -33.47% -199.56% -727.75%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -109.35% -187.18% -706.22%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -33.47% -187.19% -706.43%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -30.40% -167.29% -673.06%
Tax Burden Percent		 100.00% 98.02% 56.38% 97.67% 102.90% 89.44% 98.19% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 104.89% 100.16% 102.02% 99.20% 99.26% 99.28% 99.44% 98.95% 90.82% 89.37% 95.28%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -35.25% -394.54% -8.97% -99.72% -66.02% -63.12% -80.69% -44.79% 267.95% -69.95% -93.92%
Cash Return on Invested Capital (CROIC)		 0.00% -235.72% -93.84% -78.11% -94.61% -188.06% 0.00% 0.00% 0.00% -4,800.19% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -33.85% -68.72% -85.82%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -30.74% -61.41% -81.77%
Return on Common Equity (ROCE)		 -35.25% -394.54% -8.97% -99.72% -66.02% -63.12% -80.69% -2.81% 4,282.50% -69.95% -93.92%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -196.38% -6.43% -117.67% -58.60% -57.17% -69.02% 17.43% -29.44% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -4.48 -13 -7.94 -13 -8.09 -11 -17 -2.43 -5.47 -13 -20
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -76.54% -131.02% -494.36%
Net Nonoperating Expense Percent (NNEP)		 -19.75% 8,378.37% 176.17% -62.42% -33.50% -18.37% -24.43% -23.24% -1,249.93% -15.12% -23.95%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -74.14% -32.55% -108.69%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 91.24% 94.13% 261.68%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 118.11% 193.04% 544.54%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 209.35% 287.18% 806.22%
Earnings before Interest and Taxes (EBIT)		 -6.41 -18 -2.37 -19 -12 -16 -25 -5.86 -2.39 -18 -28
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -6.09 -18 -2.27 -19 -11 -16 -25 -5.86 -2.39 -19 -29
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.87 0.49 4.01
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.87 0.49 4.01
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.06 1.98 18.24
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.97 0.00 13.04
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -29.88 0.26 0.03 0.00 0.00 0.00 0.00 -1.38 0.00 0.00 0.00
Long-Term Debt to Equity		 -19.67 0.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.59 0.01 -0.25 -0.44 -0.62 -0.73 -0.94 -1.12 -0.33 -1.00 -1.04
Leverage Ratio		 1.18 2.16 1.43 1.20 1.18 1.15 1.10 1.62 -8.72 1.14 1.15
Compound Leverage Factor		 1.24 2.16 1.46 1.19 1.18 1.15 1.09 1.60 -7.92 1.02 1.09
Debt to Total Capital		 103.46% 20.92% 2.53% 0.00% 0.00% 0.00% 0.00% 363.39% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 35.36% 16.19% 2.53% 0.00% 0.00% 0.00% 0.00% 363.39% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 68.11% 4.74% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 710.95% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -3.46% 79.08% 97.47% 100.00% 100.00% 100.00% 100.00% -974.34% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.20 -0.13 -0.24 0.00 0.00 0.00 0.00 -2.12 0.00 0.00 0.00
Net Debt to EBITDA		 0.12 -0.05 3.68 0.00 0.00 0.00 0.00 -1.42 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -0.13 -0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.28 -0.19 -0.07 0.00 0.00 0.00 0.00 -5.10 0.00 0.00 0.00
Net Debt to NOPAT		 0.17 -0.07 1.05 0.00 0.00 0.00 0.00 -3.42 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -0.18 -0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.18 0.61 0.49
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 93.72% -1,498.22% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.39 0.36 3.59 11.09 8.51 7.71 12.92 0.32 3.84 11.11 4.91
Quick Ratio		 1.36 0.35 3.31 9.94 8.24 7.60 12.75 0.31 3.00 10.03 4.48
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 13 -24 -11 -8.01 -6.42 -12 -8.56 -4.17 -5.73 -13 -17
Operating Cash Flow to CapEx		 -12,869.69% 0.00% -2,753.85% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 40.22 0.00 0.00 0.00 0.00 0.00 0.00 -7,109.23 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -16.56 0.00 0.00 0.00 0.00 0.00 0.00 -4,382.89 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -16.69 0.00 0.00 0.00 0.00 0.00 0.00 -4,382.89 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.01 0.37 0.12
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -0.80 10 13 7.62 5.96 6.30 -2.42 -0.68 -0.42 0.28 -2.64
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -13.07 -143.46 -3.39
Increase / (Decrease) in Invested Capital		 -17 11 2.82 -5.26 -1.66 0.34 -8.72 1.74 0.26 0.70 -2.92
Enterprise Value (EV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 36 -20 52
Market Capitalization		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 43 19 73
Book Value per Share		 $0.00 $0.89 $1.46 $0.31 $4.29 $0.39 $0.34 ($16.32) $1.30 $4.75 $1.97
Tangible Book Value per Share		 $0.00 ($0.62) $0.39 $0.14 $2.45 $0.25 $0.34 ($16.32) $1.30 $4.75 $1.97
Total Capital		 1.20 12 22 16 20 25 35 3.42 7.38 39 18
Total Debt		 1.24 2.43 0.55 0.00 0.00 0.00 0.00 12 0.00 0.00 0.00
Total Long-Term Debt		 0.82 0.55 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -0.75 0.88 -8.35 -7.99 -14 -19 -37 8.32 -7.79 -39 -21
Capital Expenditures (CapEx)		 0.04 -0.00 0.45 0.00 0.00 0.00 -0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.00 -2.51 -1.37 0.12 -1.25 -2.17 -2.42 -0.68 -0.42 0.28 -2.64
Debt-free Net Working Capital (DFNWC)		 1.00 -0.95 7.53 8.11 13 16 35 3.42 7.37 39 18
Net Working Capital (NWC)		 0.57 -2.83 6.98 8.11 13 16 35 -9.00 7.37 39 18
Net Nonoperating Expense (NNE)		 2.23 5.18 -6.58 5.10 3.71 3.00 6.82 3.37 -3.30 3.53 7.16
Net Nonoperating Obligations (NNO)		 -0.75 0.88 -8.35 -7.99 -14 -19 -37 8.32 -7.79 -39 -21
Total Depreciation and Amortization (D&A)		 0.32 0.06 0.10 0.11 0.10 0.10 0.09 0.00 0.00 -1.21 -0.85
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -5.93% 2.88% -65.93%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 103.14% 402.57% 454.83%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 103.14% 402.57% 454.83%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.28) ($1.76) ($0.21) ($8.21) ($1.76) ($0.30) ($0.25) ($7.65) ($0.82) ($2.02) ($2.98)
Adjusted Weighted Average Basic Shares Outstanding		 18.61M 10.35M 12.45M 3.24M 34.60M 101.90M 101.92M 2.04M 2.66M 8.07M 9.04M
Adjusted Diluted Earnings per Share		 ($1.28) ($1.76) ($1.94) ($8.21) $6,706,509.00 $53,831,973.00 $97,626,748.00 $2,038,891.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 18.61M 10.35M 12.76M 3.24M 34.60M 101.90M 101.92M 2.04M 6.17M 8.70M 9.26M
Adjusted Basic & Diluted Earnings per Share		 ($1.28) ($1.76) $0.00 $0.00 ($1.76) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 101.58M 10.23M 50.53M 3.38M 34.60M 101.90M 101.92M 2.04M 6.17M 8.70M 9.26M
Normalized Net Operating Profit after Tax (NOPAT)		 -4.48 -13 -7.94 -8.42 -8.09 -11 -11 -2.43 -5.47 -13 -20
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -76.54% -131.02% -494.36%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -30.40% -167.29% -673.06%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -20.46 0.00 0.00 0.00 0.00 0.00 0.00 -9,990.95 0.00 0.00 0.00
NOPAT to Interest Expense		 -14.32 0.00 0.00 0.00 0.00 0.00 0.00 -4,144.59 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -20.59 0.00 0.00 0.00 0.00 0.00 0.00 -9,990.95 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -14.45 0.00 0.00 0.00 0.00 0.00 0.00 -4,144.59 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -71.30% 0.00% 0.00%

Quarterly Metrics And Ratios for CervoMed

This table displays calculated financial ratios and metrics derived from CervoMed's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 2,040,287.00 5,674,520.00 6,170,479.00 8,253,741.00 8,253,741.00 8,253,741.00 8,702,719.00 8,702,719.00 9,252,719.00 9,252,719.00 9,258,719.00
DEI Adjusted Shares Outstanding		 2,040,287.00 5,674,520.00 6,170,479.00 8,253,741.00 8,253,741.00 8,253,741.00 8,702,719.00 8,702,719.00 9,252,719.00 9,252,719.00 9,258,719.00
DEI Earnings Per Adjusted Shares Outstanding		 1.05 -0.42 -0.41 -0.28 -0.58 -0.81 -0.56 -0.72 -0.84 -0.87 -0.86
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 66.72% 91.23% 27.07% -13.19% -18.31% -46.56% -83.37% -99.60% -100.00%
EBITDA Growth		 332.56% -139.83% -355.47% -107.55% -379.82% -207.17% -114.06% -121.23% -40.51% -11.20% -47.29%
EBIT Growth		 332.56% -139.83% -355.47% -107.55% -356.80% -191.74% -104.36% -121.23% -49.00% -15.06% -52.96%
NOPAT Growth		 -322.72% -127.88% -81.93% -143.31% -41.20% -191.92% -104.35% -120.90% -49.07% -15.06% -52.95%
Net Income Growth		 343.63% -162.22% -370.55% -62.53% -321.06% -183.86% -94.65% -170.12% -62.54% -20.60% -62.73%
EPS Growth		 58.82% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 -121.40% -266.55% 3.93% -12.22% -230.78% -217.16% -173.54% -195.90% -33.18% 18.32% -105.90%
Free Cash Flow Firm Growth		 35.67% -144.51% -36.06% 0.91% -97.76% -188.58% -93.03% -180.72% -48.75% 49.52% 3.76%
Invested Capital Growth		 0.00% 38.58% 23.97% -19.63% -19.86% 167.37% 40.93% 90.08% -25.82% -1,042.37% -278.39%
Revenue Q/Q Growth		 -11.25% 63.16% -5.75% 40.12% -41.02% 11.46% -11.31% -8.33% -81.65% -97.29% -100.00%
EBITDA Q/Q Growth		 245.70% -217.99% -4.59% -15.43% -96.43% -29.53% 27.11% -24.96% -24.76% -2.51% 3.45%
EBIT Q/Q Growth		 245.70% -217.99% -4.59% -15.43% -80.27% -34.05% 26.73% -24.96% -21.41% -3.52% 2.60%
NOPAT Q/Q Growth		 -210.45% 35.09% -4.62% -15.42% -80.17% -34.18% 26.76% -24.77% -21.58% -3.57% 2.65%
Net Income Q/Q Growth		 250.85% -209.86% -6.43% 7.85% -105.17% -41.07% 27.02% -27.88% -23.46% -4.67% 1.52%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 25.19% -72.97% 43.92% -54.65% -120.50% -65.84% 51.63% -67.29% 0.76% -1.71% -21.94%
Free Cash Flow Firm Q/Q Growth		 7.06% -9.48% -7.23% 9.18% -85.49% -59.76% 28.28% -32.08% 1.71% 45.78% -36.73%
Invested Capital Q/Q Growth		 -10.46% 51.08% -148.22% 10.82% -10.68% 127.50% -317.63% 85.02% -1,303.51% -105.95% 12.62%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00%
EBITDA Margin		 137.75% -99.62% -110.55% -91.07% -303.32% -352.50% -289.69% -377.00% -2,562.85% -97,115.36% 0.00%
Operating Margin		 -175.25% -99.59% -110.55% -91.06% -278.19% -334.91% -276.55% -376.41% -2,493.79% -95,479.25% 0.00%
EBIT Margin		 137.75% -99.62% -110.55% -91.07% -278.37% -334.79% -276.56% -377.00% -2,494.17% -95,441.53% 0.00%
Profit (Net Income) Margin		 140.87% -94.85% -107.12% -70.44% -245.06% -310.17% -255.23% -356.05% -2,395.34% -92,680.38% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 102.27% 95.22% 96.89% 77.35% 88.03% 92.65% 92.29% 94.44% 96.04% 97.11% 98.18%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 41.65% 267.95% -38.42% -15.71% -43.28% -69.95% -93.42% -54.21% -71.42% -93.92% -132.76%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -4,800.19% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 53.26% -100.74% -67.70% -25.53% -91.99% -122.90% -110.54% -64.24% -386.53% -11,594.42% 0.00%
Return on Assets (ROA)		 54.47% -95.92% -65.60% -19.74% -80.99% -113.86% -102.02% -60.68% -371.22% -11,258.99% 0.00%
Return on Common Equity (ROCE)		 41.65% 4,282.50% -38.42% -15.71% -43.28% -69.95% -93.42% -54.21% -71.42% -93.92% -132.76%
Return on Equity Simple (ROE_SIMPLE)		 41.65% 0.00% -77.80% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -2.68 -1.74 -1.82 -2.10 -3.78 -5.07 -3.71 -4.63 -5.63 -5.83 -5.68
NOPAT Margin		 -175.25% -69.72% -77.39% -63.75% -194.74% -234.44% -193.59% -263.49% -1,745.65% -66,835.47% 0.00%
Net Nonoperating Expense Percent (NNEP)		 92.58% 237.34% -5.81% -0.67% -3.42% -7.01% -5.68% -3.85% -5.67% -7.54% -9.50%
Return On Investment Capital (ROIC_SIMPLE)		 - -23.54% -34.04% -4.20% -8.28% -12.93% -10.72% -13.85% -21.65% -32.00% -53.48%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 157.89% 84.95% 90.66% 76.37% 113.98% 107.13% 124.25% 185.77% 721.19% 28,765.05% 0.00%
R&D to Revenue		 117.36% 114.65% 119.90% 114.70% 264.21% 327.78% 252.30% 290.64% 1,872.60% 66,814.20% 0.00%
Operating Expenses to Revenue		 275.25% 199.59% 210.55% 191.06% 378.19% 434.91% 376.55% 476.41% 2,593.79% 95,579.25% 0.00%
Earnings before Interest and Taxes (EBIT)		 2.10 -2.48 -2.59 -3.00 -5.40 -7.24 -5.30 -6.63 -8.05 -8.33 -8.11
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 2.10 -2.48 -2.59 -3.00 -5.88 -7.62 -5.55 -6.63 -8.27 -8.47 -8.18
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.98 5.87 26.94 2.83 2.64 0.49 2.30 1.64 2.88 4.01 3.44
Price to Tangible Book Value (P/TBV)		 0.98 5.87 26.94 2.83 2.64 0.49 2.30 1.64 2.88 4.01 3.44
Price to Revenue (P/Rev)		 2.03 6.06 17.78 14.64 11.97 1.98 8.55 7.03 12.15 18.24 17.46
Price to Earnings (P/E)		 2.36 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 42.30% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 4.97 17.00 9.37 7.34 0.00 4.77 2.72 7.72 13.04 11.28
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.09 -0.33 -1.11 -1.03 -1.03 -1.00 -1.04 -1.01 -1.03 -1.04 -1.06
Leverage Ratio		 1.26 -8.72 1.22 1.07 1.10 1.14 1.17 1.09 1.11 1.15 1.19
Compound Leverage Factor		 1.29 -8.30 1.18 0.83 0.97 1.06 1.08 1.03 1.07 1.12 1.17
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -1.86 3.15 23.18 25.81 21.40 1.45 10.24 4.74 6.02 3.37 -5.71
Noncontrolling Interest Sharing Ratio		 0.00% -1,498.22% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.81 3.84 2.99 14.73 15.04 11.11 9.78 8.20 6.66 4.91 3.36
Quick Ratio		 4.23 3.00 2.39 14.03 14.37 10.03 8.94 7.22 5.93 4.48 2.87
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1.82 -2.00 -2.14 -1.95 -3.61 -5.76 -4.13 -5.46 -5.37 -2.91 -3.98
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.39 1.01 0.61 0.28 0.33 0.37 0.40 0.17 0.16 0.12 0.08
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -0.85 -0.42 -1.03 -0.92 -1.02 0.28 -0.61 -0.09 -1.28 -2.64 -2.31
Invested Capital Turnover		 -10.95 -13.07 -6.76 -11.42 -10.77 -143.46 -11.33 -15.36 -5.35 -3.39 -1.43
Increase / (Decrease) in Invested Capital		 -0.85 0.26 0.33 -0.15 -0.17 0.70 0.42 0.83 -0.26 -2.92 -1.70
Enterprise Value (EV)		 -1.00 36 137 90 74 -20 44 21 48 52 24
Market Capitalization		 9.43 43 144 141 121 19 80 55 75 73 36
Book Value per Share		 $4.69 $1.30 $0.86 $6.06 $5.53 $4.75 $3.98 $3.84 $2.81 $1.97 $1.15
Tangible Book Value per Share		 $4.69 $1.30 $0.86 $6.06 $5.53 $4.75 $3.98 $3.84 $2.81 $1.97 $1.15
Total Capital		 9.57 7.38 5.34 50 46 39 35 33 26 18 11
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -10 -7.79 -6.37 -51 -47 -39 -35 -34 -27 -21 -13
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.04 -0.42 -1.06 -0.98 -1.09 0.28 -0.61 -0.09 -1.28 -2.64 -2.31
Debt-free Net Working Capital (DFNWC)		 9.38 7.37 5.30 44 46 39 35 33 26 18 11
Net Working Capital (NWC)		 9.38 7.37 5.30 44 46 39 35 33 26 18 11
Net Nonoperating Expense (NNE)		 -4.83 0.63 0.70 0.22 0.98 1.64 1.18 1.63 2.10 2.26 2.29
Net Nonoperating Obligations (NNO)		 -10 -7.79 -6.37 -51 -47 -39 -35 -34 -27 -21 -13
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 -0.48 -0.38 -0.25 0.00 -0.22 -0.15 -0.07
Debt-free, Cash-free Net Working Capital to Revenue		 -22.45% -5.93% -13.17% -10.12% -10.86% 2.88% -6.55% -1.18% -20.82% -65.93% -110.50%
Debt-free Net Working Capital to Revenue		 201.53% 103.14% 65.61% 456.99% 452.62% 402.57% 372.09% 429.98% 422.28% 454.83% 508.17%
Net Working Capital to Revenue		 201.53% 103.14% 65.61% 456.99% 452.62% 402.57% 372.09% 429.98% 422.28% 454.83% 508.17%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $2.31 ($0.41) ($0.27) ($0.55) ($0.79) ($0.56) ($0.70) ($0.84) ($0.88) ($0.86)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 2.66M 6.17M 8.70M 8.70M 8.07M 8.70M 8.95M 9.25M 9.04M 9.26M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($0.55) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 6.17M 8.25M 8.25M 8.70M 8.70M 8.70M 9.25M 9.25M 9.26M 9.26M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 6.17M 8.25M 8.25M 8.25M 8.70M 8.70M 9.25M 9.25M 9.26M 9.26M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.87 -1.74 -1.82 -2.10 -3.78 -5.07 -3.71 -4.63 -5.63 -5.83 -5.68
Normalized NOPAT Margin		 -122.67% -69.72% -77.39% -63.75% -194.74% -234.44% -193.59% -263.49% -1,745.65% -66,835.47% 0.00%
Pre Tax Income Margin		 140.87% -94.85% -107.12% -70.44% -245.06% -310.17% -255.23% -356.05% -2,395.34% -92,680.38% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 36.50% -71.30% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

CervoMed Financials - Frequently Asked Questions

According to the most recent income statement we have on file, CervoMed's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

CervoMed's net income appears to be on an upward trend, with a most recent value of -$26.97 million in 2025, rising from -$6.72 million in 2015. The previous period was -$16.29 million in 2024. See CervoMed's forecast for analyst expectations on what's next for the company.

CervoMed's total operating income in 2025 was -$28.29 million, based on the following breakdown:
  • Total Gross Profit: $4.01 million
  • Total Operating Expenses: $32.30 million

Over the last 10 years, CervoMed's total revenue changed from $0.00 in 2015 to $4.01 million in 2025, a change of 400,651,000.0%.

CervoMed's total liabilities were at $4.66 million at the end of 2025, a 20.0% increase from 2024, and a 100.8% increase since 2015.

In the past 10 years, CervoMed's cash and equivalents has ranged from $1.55 million in 2016 to $37.31 million in 2021, and is currently $8.24 million as of their latest financial filing in 2025.

Over the last 10 years, CervoMed's book value per share changed from 0.00 in 2015 to 1.97 in 2025, a change of -89,622.7%.


Related Companies

Financial statements for NASDAQ:CRVO last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel